With the advent of gefitinib, the median OS of patients with NSCLC harboring EGFR tyrosine kinase inhibitors (EGFR-TKIs) sensitizing mutation has dramatically improved to 20 months [10, 11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.